Yes, the circumstances may have changed somewhat with the recent failure of competitors. After chatting with an expert in the field it seems there is a growing belief that OPT302 is the most likely successful candidate to improve outcomes in combination with VEGFA inhibitors.
My view is that the recent sell down has created an opportunity for investors. Novartis was willing to pay USD1 billion for a combination therapy. Maybe the stakes are even higher now, and maybe licensing combination therapies with multiple companies products would provide an even better return.
- Forums
- ASX - By Stock
- Ann: Trading Halt
Yes, the circumstances may have changed somewhat with the recent...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
48.5¢ |
Change
-0.010(2.02%) |
Mkt cap ! $594.0M |
Open | High | Low | Value | Volume |
49.5¢ | 50.8¢ | 47.8¢ | $154.8K | 315.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 24876 | 48.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 5109 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 30326 | 0.480 |
11 | 67340 | 0.475 |
8 | 33087 | 0.470 |
6 | 26836 | 0.465 |
3 | 180698 | 0.460 |
Price($) | Vol. | No. |
---|---|---|
0.485 | 1808 | 6 |
0.490 | 21541 | 10 |
0.495 | 23417 | 5 |
0.500 | 42012 | 10 |
0.505 | 24776 | 7 |
Last trade - 14.16pm 20/08/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |